FAT REDISTRIBUTION AND METABOLIC ABNORMALITIES
脂肪重新分布和代谢异常
基本信息
- 批准号:6588124
- 负责人:
- 金额:$ 19.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-01 至 2002-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS therapy HIV infections adipose tissue antiAIDS agent blood chemistry blood glucose blood lipid body composition clinical research cortisol diabetes mellitus genetics dietary lipid disease /disorder proneness /risk endocrine gland /system family genetics glucose tolerance test human subject insulin sensitivity /resistance metabolism disorder metformin nutrient intake activity nutrition related tag pathologic process pharmacology quality of life radiography testosterone
项目摘要
A syndrome of fat redistribution and metabolic abnormalities is being reported with increasing frequency in persons with HIV infection, most often in association with the class of antiretroviral drug, protease inhibitors. Common manifestations include abdominal obesity, thinning of the extremities, dorsocervical fat accumulation, insulin resistance, and dyslipidemias. The etiology, mechanism, and treatment of this syndrome are unclear. Given the tremendous improvements in morbidity and mortality seen with protease inhibitors (PIs), and the risk of viral resistance, discontinuation of these medications is currently not appropriate management for fat distribution of the accompanying metabolic abnormalities. Although the short-term outlook for HIV disease has greatly improved, the cardiovascular consequences of abdominal obesity, insulin resistance, and lipid abnormalities are well-established in HIV-seronegative populations. The long-term objectives of this project are: to clarify the role of PIs and other highly-active antiretroviral therapy (HAART) regimens in causing the syndrome; to recognize non-pharmacologic pre-disposing factors; to understand the course of the syndrome's development; and to test a possible treatment for abdominal adiposity. This project includes: a) analyses of relevant data collected from the NFL cohort; b) a metabolically more intensive cohort study of 50 persons not currently taking PIs, 25 of whom are planning to start PIs; and c) a randomized clinical trial of the management of insulin resistance with diet and metformin hydrochloride (1.5 g/day) for 6 months in 50 persons with HAART-associated abdominal obesity.
在艾滋病毒感染者中,脂肪重新分布和代谢异常综合征的报道越来越频繁,最常见的是与抗逆转录病毒药物、蛋白酶抑制剂相关。常见的表现包括腹部肥胖、四肢消瘦、颈背脂肪堆积、胰岛素抵抗和血脂异常。该综合征的病因、机制和治疗尚不清楚。鉴于蛋白酶抑制剂 (PI) 可以显着改善发病率和死亡率,并且存在病毒耐药性的风险,目前停用这些药物对于治疗伴随的代谢异常的脂肪分布并不合适。尽管艾滋病毒疾病的短期前景已大大改善,但腹部肥胖、胰岛素抵抗和血脂异常对心血管的影响在艾滋病毒血清阴性人群中已得到证实。该项目的长期目标是: 阐明 PI 和其他高效抗逆转录病毒治疗 (HAART) 方案在引起该综合征中的作用;识别非药物诱发因素;了解该综合征的发展过程;并测试腹部肥胖的可能治疗方法。该项目包括: a) 对从 NFL 队列收集的相关数据进行分析; b) 对 50 名目前未服用 PI 的人进行一项代谢更密集的队列研究,其中 25 人计划开始服用 PI; c) 在 50 名 HAART 相关腹部肥胖患者中进行为期 6 个月的通过饮食和盐酸二甲双胍(1.5 g/天)治疗胰岛素抵抗的随机临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ABBY H SHEVITZ其他文献
ABBY H SHEVITZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ABBY H SHEVITZ', 18)}}的其他基金
THE METABOLIC EFFECTS OF ANTI-HIV THERAPY IN MACAQUES
抗艾滋病毒治疗对猕猴的代谢影响
- 批准号:
6940242 - 财政年份:2003
- 资助金额:
$ 19.62万 - 项目类别:
相似国自然基金
艾滋病毒感染后疾病进展和治疗的动力学模型与研究
- 批准号:10971163
- 批准年份:2009
- 资助金额:26.0 万元
- 项目类别:面上项目
用细菌传递RNA干扰经肠道黏膜免疫系统治疗艾滋病毒感染
- 批准号:30972624
- 批准年份:2009
- 资助金额:30.0 万元
- 项目类别:面上项目
艾滋病毒感染病者口腔疣状肿块的细胞生物学特性
- 批准号:30660199
- 批准年份:2006
- 资助金额:20.0 万元
- 项目类别:地区科学基金项目
HIV-1 tat 蛋白及其相互作用的细胞因子功能性研究
- 批准号:30570069
- 批准年份:2005
- 资助金额:8.0 万元
- 项目类别:面上项目
相似海外基金
The Gut-Liver Axis in HIV-Related Non-Alcoholic Fatty Liver Disease
HIV 相关非酒精性脂肪肝中的肠肝轴
- 批准号:
10762284 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency
雌激素替代对绝经后 ART 相关合并症和病毒潜伏期的影响
- 批准号:
10326734 - 财政年份:2021
- 资助金额:
$ 19.62万 - 项目类别:
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency
雌激素替代对绝经后 ART 相关合并症和病毒潜伏期的影响
- 批准号:
10468267 - 财政年份:2021
- 资助金额:
$ 19.62万 - 项目类别:
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency
雌激素替代对绝经后 ART 相关合并症和病毒潜伏期的影响
- 批准号:
10624286 - 财政年份:2021
- 资助金额:
$ 19.62万 - 项目类别:
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV
通过 CCR2 和 CCR5 双重拮抗作用减少 HIV 感染者的动脉炎症并改善代谢健康
- 批准号:
10475255 - 财政年份:2020
- 资助金额:
$ 19.62万 - 项目类别: